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The aim of this study was to analyse the impact of epidermal growth factor receptor (EGFR), thymidylate synthase (TS),
dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), aurora kinase (ARK) A/B, and excision repair cross-
complementing gene 1 (ERCC1) on the efficacy of adjuvant chemotherapy with 5-fluorouracil and cisplatin (FP) after curative gastric
resection. Normal and cancer tissue were separately obtained from gastrectomy samples of 153 patients with AJCC stage III–IV (M0)
who subsequently treated with adjuvant FP chemotherapy. TS, DPD, TP, ERCC1, and ARK proteins were measured by
immunohistochemistry (IHC). EGFR expression was investigated using a standardized IHC with the EGFR PharmDx assay.
Amplification of EGFR gene was analysed using fluorescent in situ hybridisation (FISH). In multivariate analysis, stage, ratio of positive to
removed lymph nodes, and EGFR expression were significant prognostic factors for overall survival. Patients with higher EGFR
expression had better overall survival than those with lower expression (relative risk: 0.475 (95% confidence interval, 0.282–0.791,
P¼0.005). Low EGFR expression might be a predictive marker for relapse in curative resected stage III–IV (M0) gastric cancer
patients who received adjuvant FP chemotherapy.
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The prognostic and predictive roles of epidermal growth factor
receptor (EGFR) expression in gastric cancer remain controversial,
and the reported frequencies of EGFR expression are varied in
gastric cancer (Gamboa-Dominguez et al, 2004; Matsubara et al,
2008b). In the past, high levels of EGFR were reported as a poor
prognostic factor for overall survival (OS) in resectable gastric
cancer patients who did not receive chemotherapy (Garcia et al,
2003; Galizia et al, 2007). In contrast, high levels of EGFR were
reported as a positive prognostic factor in patient group who
received 5-fluorouracil (FU)-containing chemotherapy (Al-Batran
et al, 2008a; Matsubara et al, 2008a). Thymidylate synthase (TS),
thymidine phosphorylase (TP), and dihydropyrimidine dehydro-
genase (DPD) are known key enzymes in the metabolism of 5-FU
and play a role in resistance to fluoropyrimidines. Thymidylate
synthase expression level is presumed to influence response to
5-FU-containing chemotherapy, although TS is not unanimously
recognised as a determinant of 5-FU sensitivity (Danenberg, 2004;
Park and Lenz, 2006). Thymidine phosphorylase catalyses the
reversible phosphorylation of thymidine to thymine 2-deoxy-
ribose-1-phosphate, and increases the conversion of 5-FU to its
active metabolites, which play an important role in the inhibition
of TS (Tahara et al, 2004). Dihydropyrimidine dehydrogenase is
the initial and rate-limiting enzyme in the catabolism of 5-FU.
Although the role of DPD levels in tumours have not been firmly
established as a prognostic factor for clinical responsiveness, there
is ample evidence that a DPD deficiency is associated with severe
toxicity after 5-FU administration (van Kuilenburg, 2004).
Expression of the excision repair cross-complementing gene 1
(ERCC1) may play a role in human tumours because it is essential
for nucleotide excision repair and influences genomic instability
(Chen et al, 2000). For example, low gene expression levels of
ERCC1 were associated with a superior response to 5-FU and
cisplatin chemotherapy (FP) in primary gastric cancer (Metzger
et al, 1998), and ERCC1 protein expression levels were found to be
inversely associated with response. Excision repair cross-comple-
menting gene 1 may possibly have a role in the clinical resistance Revised 8 January 2009; accepted 19 January 2009
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sto platinum compounds in gastric cancer patients (Kwon et al,
2007). The Aurora kinases, a family of mitotic regulators, have
received much attention as potential targets of new drugs (Warner
et al, 2006) and in their association with chemoresistance to
platinum agents (Yang et al, 2006). However, none of these
markers have previously been evaluated in an adjuvant setting in
high-risk gastric cancer patients undergoing potentially curative
surgery.
MATERIALS AND METHODS
Study population
From the database of Seoul National University Hospital, we
identified a total of 5387 patients who underwent gastrectomy
between November 1995 and November 2003. Patients with a
diagnosis of histologically proven gastric cancer, who received a
curative gastrectomy with D2 dissection and adjuvant chemother-
apy consisting of 5-FU and cisplatin were identified. Cisplatin
(60mgm
 2 as 15min i.v. infusion) followed by 5-FU (1200mgm
 2
as 12h continuous i.v. infusion for 4 days) was given in 21-day
cycles. The following eligibility criteria were used for patients’
enrollment: age o75 years; free from distant metastatic disease;
stages IIIA, IIIB, and IV (only non-metastatic cases, T4 N1-3
and T1-3 N3; AJCC Cancer Staging, 6th edition); no prior
chemotherapy or radiotherapy; World Health Organisation
(WHO) performance status p2; adequate baseline organ function,
defined as WBC count X4000cells per ml, platelet count
X100000cells per ml, serum bilirubin level p1.5mgml
 1, serum
creatinine level p2.0mg/100ml, serum albumin level X3.0mg/
100ml, no severe uncontrolled comorbidities (e.g., myocardial
infarction in the last 12 months); no second malignancies; and
informed consent.
Patient follow-up
In the absence of symptoms, physical examination was performed
every 3–4 months for 5 consecutive years. Follow-up assessment
consisted of physical examination, a complete blood count, liver
function test, chest radiography, and abdominal ultrasound or CT
scan, every 3–6 months for 5 years. Toxicities were graded
according to NCI-CTC version 2. The site and date of the first
relapse and the date of death, if the patient died, were recorded.
Survival was calculated from beginning of surgery until the last
follow-up or death from any cause; patients who were alive at the
last follow-up were censored at that time. Patients who were taken
off study or who died before progression were censored at the time
when they were taken off from the study. Survival data were
confirmed either by medical records or by the death reports from
the Korea Central Cancer Registry.
Tissue sampling
Cancerous and adjacent normal tissues were obtained from the
surgically resected and paraffin-embedded primary gastric cancer
specimens of the patients. Samples were examined histologically
for the presence of tumour cells.
Tissue microarray methods
Core tissue biopsy specimens (2mm in diameter) were obtained
from individual paraffin-embedded gastric tumours (donor
blocks) and arranged in a new recipient paraffin block (tissue
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Figure 1 Typical examples of positive immunohistochemical staining. A: TS ( ) B: TS (2þ) C: DPD ( ) D: DPD (2þ). E: ERCC1 ( ) F: ERCC1 (2þ)
G: TP ( ) H: TP (2þ). I: ARK1 ( ) J: ARK1 (2þ) K: ARK2 ( ) L: ARK2 (2þ). In the immunohistochemical (IHC) analysis of thymidylate synthase (TS),
dihydropyrimidine dehydrogenase (DPD), excision repair cross-complementing gene 1 (ERCC1) and thymidine phosphorylase (TP), the degree of IHC
reactivity was graded from 0 to 3þ according to the cytoplasmic staining.
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sarray block) using a trephine apparatus (Superbiochips Labora-
tories, Seoul, Korea). Each tissue array block contained up to 60
cases, allowing a total of 153 pairs to be contained in six array
blocks. An adequate case was defined as one with a tumour
occupying more than 10% of the core area. Each block contained
an internal control consisting of non-neoplastic gastric mucosa
from adjacent tissue. Sections of 4mm were cut from each tissue
array block, deparaffinised, and dehydrated. As shown earlier,
staining results obtained from different intratumoural areas in
various cancers correspond with each other (Lee et al, 2007), and a
core was sampled in each case.
Immunohistochemistry (IHC)
Immunohistochemical staining for TS, TP, and ERCC1 was
performed using an ABC method (labelled biotin) after a
microwave antigen retrieval process. Mouse monoclonal anti-
bodies of TS, TP, and ERCC1 were obtained from Neomarkers,
Fremont, CA, USA. Staining intensity and stained tumour cell
percentages were measured. Stained cell percentage was multiplied
by the staining intensity (0–3þ), which resulted in an IHC score
ranging from 0 to 300 for each cell type, as described previously
(Ren et al, 2004). Rabbit polyclonal antibodies to ARK-1 and
ARK-2 were obtained from Santa Cruz Biotechnology Inc., CA,
USA. Immunohistochemical staining for EGFR was performed on
the tissue microarray slides using the EGFR PharmDx kit (DAKO
Cytomation) according to the manufacturer’s instructions. The
positive samples were classified further into 1þ,2 þ, and 3þ,
based on their staining intensity. The highest staining intensity of
all tissue cores from the same tumour was scored as the final
immunohistochemical result. Pathologists unaware of clinical
outcomes independently scored the immunohistochemical stain-
ing. We determined the appropriate cutoff value for the IHC score
of TS, TP, and ERCC1 with the highest sensitivity and specificity by
the receiver operating characteristic (ROC) curve method. Typical
staining intensities for TS, DPD, ERCC1, TP, ARK-1, and ARK-2
are shown in Figure 1.
EGFR fluorescent in situ hybridization (FISH) analysis
EGFR (7p12) gene amplification was determined using a DNA
probe set (LSI EGFR/CEP 7; Vysis, Downers Grove, IL, USA)
consisting of a SpectrumOrange-labelled EGFR (locus)-specific
probe and a SpectrumGreen-labelled probe that hybridises to the
centromeric region of chromosome 7 according to protocols
described elsewhere (Mitsui et al, 2007).
Statistical analysis
Statistical analysis was performed on a personal computer using
SPSS 12.0K for windows (SPSS Inc. Chicago, IL, USA). The survival
rate was calculated using the Kaplan–Meier method, and a
statistical analysis was performed using log-rank test. Multi-
variable analysis of prognostic factors was conducted by Cox
proportional hazards model; Po0.05 was considered statistically
significant.
RESULTS
Between 1 November 1995 and 30 November 2003, a total of 153
patients were eligible for the study. The demographic character-
istics are outlined in Table 1. The group consisted of 108 men
(70.6%) and 48 women (29.4%) with a median age of 52.0 (range:
15–72) years. Median follow-up duration was 72.9 months (range:
2.0–135.0 months). Demographic and clinical data are described
in our earlier report in detail.
Expression of EGFR, TS, TP, DPD, and ERCC1 proteins
Epidermal growth factor receptor expression using the PharmDx
kit revealed a score of 0 in 29 patients (19.3%), 1þ in 56 patients
(37.3%), 2þ in 56 patients (37.3%), and 3þ in 9 patients (6.0%).
Epidermal growth factor receptor expression had no significant
association with clinicopathologic variables, such as age, gender,
stage, PS, Lauren’s classification, and Borrmann type and
differentiation. Fluorescent in situ hybridization analysis of EGFR
was evaluable in a total of 135 patients, which showed high
polysomy in three patients (2.2%) and amplification in four
patients (3.0%). Epidermal growth factor receptor expression had
no significant correlation with FISH positivity. The expression
levels of TS, TP, and ERCC1, as determined by IHC, in cancer
tissue were not significantly different in relapsed and non-relapsed
patients. These expression levels were not different between stages.
However, expression of TP and ERCC1 was significantly higher in
cancerous tissue than in normal tissue (Po0.0001). No significant
correlation between TP and ERCC1 levels was found in cancerous
and normal tissues. Dihydropyrimidine dehydrogenase expression
levels in cancerous tissues were not significantly different in
relapsed and non-relapsed cases; however, DPD levels were
Table 1 Characteristics of patients and tumours
Patients
Characteristics Number %
All patients 153
Age (years)
Median 52
Range 15–72
Sex
Male 105 68.6
Female 48 31.4
ECOG performance status
0–1 132 91.5
2 13 8.5
Operation
Subtotal gastrectomy 61 39.9
Total gastrectomy 92 60.1
Location
Proximal 30 19.6
Distal 123 80.4
Pathology
Adenocarcinoma 135 88.2
Signet ring cell carcinoma 18 11.8
Lauren classification
Intestinal 44 28.8
Diffuse 86 56.2
Mixed 19 12.4
Borrmann type
1 1 0.7
2 13 8.5
3 95 62.1
4 44 28.8
Stage
a
IIIA 51 33.3
IIIB 32 20.9
IV 70 45.8
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
aAmerican Joint
Committee on Cancer Staging manual, 6th edition.
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ssignificantly lower in cancerous tissue (Po0.0001). We could not
analyse the correlation between cancerous and normal tissue DPD
levels, because normal tissues expressed DPD with uniform
intensity and distribution; ERCC1 expression was positively
correlated with EGFR expression (P¼0.047, ANOVA test).
Expression of ARK1 and ARK2 were positive in 68.1 and 69.3%,
respectively.
Prognostic factors
We performed univariate analyses of biomarkers associated with
relapse and survival (Table 2). Epidermal growth factor receptor
and TP expressions were significant prognostic factor for OS in
univariate analysis (Table 2, Figure 2). However, expression of TS
and ARK1 were not significantly associated with relapse and
survival. Parameters with P-values of p0.10 were included in the
multivariate analysis using the Cox proportional hazards. The
positive LN ratio was an independent prognostic marker for both
disease-free survival (DFS) and OS. Relapse and survival were
significantly influenced by stage, the ratio of invaded, resected
lymph nodes, and by the expression of TP, ERCC1, and EGFR
(Table 3). Low EGFR expression was an independent biomarker for
predicting poor OS in multivariate analysis. The relationship
between the coupled expression of TP and EGFR and clinical
outcomes are shown in Figure 3A and B. Patients with higher TP
and EGFR expression showed longer DFS (26.0 vs 16.0 months,
P¼0.05) and OS (45.3 vs 23.6 months, P¼0.009) than the other
patients. After adjustments for stage, LN ratio, and TP expression,
EGFR expression was remained as a significant prognostic factor
for both DFS and OS (Figure 4A and B). The DFS and OS were not
significantly influenced according to the grade of EGFR expression
or EGFR amplification or polysomy detected by FISH.
DISCUSSION
Epidermal growth factor receptor expression was a prognostic
factor in our study, but the prognostic role of EGFR in gastric
cancer needs to be further elucidated. Some reports showed that
high levels of EGFR expression are associated with more distant
metastasis, more advanced stage, and poorer OS (Garcia et al,
2003; Gamboa-Dominguez et al, 2004; Galizia et al, 2007). In
advanced gastric cancer patients treated mainly with 5-FU or
cisplatin-based chemotherapy, lower expression of EGFR mRNA
than the cutoff value was a strong predictor of poor survival by
multivariate analysis (Matsubara et al, 2008a). Interestingly, the
authors also showed that high DPD and ERCC1 expressions were
significant predictors of poor survival. Another recent report
showed that EGFR expression was a positive prognostic factor in
patients with AGC (Al-Batran et al, 2008a), which was a
retrospective analysis from the phase III trial comparing 5-FU,
folinic acid plus either oxaliplatin vs cisplatin (Al-Batran et al,
2008b). There has also been evidence suggesting that cytotoxic
chemotherapy is more effective among patients with high EGFR
expression than in those with low EGFR expression (Ceppi et al,
2006; Vallbohmer et al, 2006). The prognostic and predictive roles
of EGFR expression in gastric cancer thus remain controversial.
Differences in EGFR expression among these studies may also be
attributed to the lack of an established immunohistochemical
scoring system commonly used to evaluate gastric cancer. Other
prognostic variables, such as insulin-like growth factor type 1
receptor (Matsubara et al, 2008c) and class I histone deacetylase
expression (Weichert et al, 2008) might also have confounding
interactions.
In gastric cancer patients, higher TP expression was reported in
cancerous tissues compared with the adjacent normal tissues
(Maeda et al, 1996; Tanigawa et al, 1996; Kakeji et al, 1999) by IHC
Table 2 Univariate analyses of clinical prognostic factors (P-values)
Disease-free survival Overall survival
Factors Number of patients RR of relapse and 95% CI P-value RR of dying and 95% CI P-value
TS 0.712 0.153
o25 77 1 1
X25 74 0.927 (0.620–1.387) 0.725 (0.467–1.127)
TP 0.10 0.043
o25 66 1 1
X25 85 0.714 (0.477–1.070) 0.638 (0.413–0.986)
ERCC1 0.060 0.051
o17.5 65 1 1
X17.5 86 0.677 (0.451–1.017) 0.644 (0.414–1.001)
EGFR PharmDx 0.115 0.045
Negative 29 1 1
1+ to 3+ 113 0.676 (0.415–1.101) 0.605 (0.370–0.988)
ARK1 0.139 0.297
Negative 45 1 1
Positive 96 1.385 (0.899–2.134) 0.791 (0.509–1.229)
ARK2 0.101 0.067
Negative 46 1 1
Positive 104 0.712 (0.474–1.069) 0.678 (0.448–1.028)
EGFR FISH 0.775 0.440
Negative 111 1 1
Positive 18 0.918 (0.510–1.652) 0.779 (0.413–1.469)
Abbreviations: ARK¼aurora kinase; CI¼confidence interval; EGFR¼epidermal growth factor receptor; ERCC1¼excision repair cross-complementing gene 1; TP¼thymidine
phosphorylase; TS¼thymidylate synthase; RR¼relative risk. Relative risk adjusted for stage. If the relative risk is 41, the relative risk can be thought as the average increased risk
of relapse or dying compared with the reference group. The group with the ratio equal to 1 is the reference group.
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sand ELISA. These studies indicated that TP expression is closely
correlated with cancer invasion, haematogenous metastasis, lymph
node metastasis, venous invasion, lymphatic invasion, and
microvascular invasion. In our study, IHC scores from cancerous
tissue were significantly higher than those of normal tissue. Higher
TP expression might be a prognostic marker for OS, but the role of
TP expression in gastric cancer also needs to be further elucidated.
Many reports have indicated that DPD activities are unaltered in
gastric cancer (Ishikawa et al, 1999; Terashima et al, 2002).
However, it was also reported that gastric carcinomas have
significantly higher DPD activities than normal mucosa (Nakata
et al, 2004). Another report showed that DPD expression in cancer
cells, but not in stromal cells, could predict the efficacy of 5-FU
chemotherapy in patients with T3 gastric carcinoma (Hisamitsu
et al, 2004). In our study, the IHC scores of cancerous tissues were
significantly lower than those of normal tissues, and no significant
difference was observed between relapsed and non-relapsed
patients in terms of IHC scores.
Decreased ERCC1 expression was associated with a superior
response to 5-FU/cisplatin in primary intact gastric cancer patients
(Metzger et al, 1998). The degree of ERCC1 protein expression was
found to be inversely associated with this response, which is
potentially relevant to clinical resistance to platinum compounds
(Kwon et al, 2007). In patients with curatively resected gastric
cancer, it was shown that increased ERCC1 expression was
correlated with improved outcome (Baek et al, 2006). In patients
with completely resected non-small-cell lung cancer, ERCC1-
negative tumours showed greater benefit from cisplatin-based
adjuvant chemotherapy compared with ERCC1-positive tumours
(Olaussen et al, 2006). Reports concerning ERCC1 in resected lung
cancer suggest that ERCC1 overexpression may improve treatment
outcome by reducing DNA mutations during cancer progression
(Simon et al, 2005; Lee et al, 2008).
In this study, low ERCC1 expression was associated with poor
survival, but ERCC1 expression level was also closely associated
with EGFR expression level. After multivariate analysis, the impact
of ERCC1 on survival disappeared. To our knowledge, the ERCC1
protein expression between cancer and normal tissues has never
been compared, although a report suggested that no significant
difference exists in ERCC1 mRNA expression (Warnecke-Eberz
et al, 2004). Further prospective studies will be needed to resolve
this issue.
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Figure 2 Kaplan–Meier estimates of (A) disease-free survival and (B)
overall survival of the patients according to the expression of epidermal
growth factor receptor (EGFR).
Table 3 Multivariate analyses of clinical prognostic factors
Disease-free survival Overall survival
Factors Number of patients RR of relapse and 95% CI P-value RR of dying and 95% CI P-value
Positive LN/resected LN 0.041 0.029
o0.3 45 1 1
0.3–0.7 75 0.941 (0.538–1.646) 0.858 (0.470–1.566)
40.7 33 1.857 (0.925–3.728) 1.780 (0.865–3.663)
Stage 0.072 0.016
IIIA 51 1 1
IIIB 32 1.599 (0.890–2.873) 1.669 (0.885–3.145)
IV 70 1.874 (1.060–3.314) 2.452 (1.331–4.519)
EGFR PharmDx 0.051 0.005
02 9 1 1
1+ to 3+ 113 0.609 (0.370–1.002) 0.475 (0.282–0.791)
TP expression 0.077
o25 66 1
X25 85 0.681 (0.445–1.042)
Abbreviations: RR¼relative risk, CI¼confidence interval. A backward likelihood ratio approach was used to select factors for multivariate analysis. If the RR is 41, the relative
risk can be thought as the average increased risk of relapse or dying compared with the reference group. The group with the ratio equal to 1 is the reference group. P-value is
based on log-rank test.
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sEarlier studies evaluated the expression of pharmacogenomic
markers as a group. For example, patients with low TS, TP, and
DPD gene expression showed prolonged survival over patients
expressing high levels of these genes (Salonga et al, 2000).
The main differences between this and the current study are
(1) analysis of mRNA vs protein, (2) colorectal cancer vs gastric
cancer, and (3) a metastatic or disseminated setting vs an adjuvant
setting. No study has been conducted on the evolution of these
pharmacogenomic markers during cancer progression in an
adjuvant setting. Therefore, further pharmacogenomic studies on
adjuvant treatments are required.
In conclusion, high expression of EGFR might be a good
predictive marker of relapse and survival in curatively resected
stage III–IV (M0) gastric cancer patients who received adjuvant
5-FU and cisplatin chemotherapy. Both EGFR expression, the
coupled expression of TP and EGFR, and the LN ratio might be
useful predictive markers for patient survival. On the other hand,
there was no relationship in this study between clinical outcome
and the pharmacogenetic markers reported in earlier studies, such
as TS, DPD, and ERCC1. This suggests that these markers might
not correlate with chemosensitivity to the FP treatment in gastric
cancer patients. Further investigation is necessary, using prospec-
tive analysis of a larger cohort in a randomised controlled trial of
adjuvant chemotherapy consisting of fluoropyrimidine and
platinum agents.
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